Rubius Therapeutics, Inc. (RUBY): Price and Financial Metrics

Rubius Therapeutics, Inc. (RUBY): $0.06

0.00 (2.70%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

Add RUBY to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#153 of 398

in industry

RUBY Price/Volume Stats

Current price $0.06 52-week high $0.38
Prev. close $0.06 52-week low $0.00
Day low $0.06 Volume 755,800
Day high $0.06 Avg. volume 1,154,788
50-day MA $0.02 Dividend yield N/A
200-day MA $0.02 Market Cap 5.16M

RUBY Stock Price Chart Interactive Chart >


Rubius Therapeutics, Inc. (RUBY) Company Bio


Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.


RUBY Latest News Stream


Event/Time News Detail
Loading, please wait...

RUBY Latest Social Stream


Loading social stream, please wait...

View Full RUBY Social Stream

Latest RUBY News From Around the Web

Below are the latest news stories about RUBIUS THERAPEUTICS INC that investors may wish to consider to help them evaluate RUBY as an investment opportunity.

Why Is Atreca (BCEL) Stock Up Today?

Atreca (BCEL) stock is getting a boost on Tuesday as the biopharmaceutical company continues a recent rally connected to insider buying.

William White on InvestorPlace | February 14, 2023

Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today?

Rubius Therapeutics (RUBY) stock is heading higher on Tuesday despite a lack of news from the cellular medicines company.

William White on InvestorPlace | February 14, 2023

Why Is T2 Biosystems (TTOO) Stock Down 21% Today?

T2 Biosystems (TTOO) stock is falling hard on Tuesday as investors react to a proposed public offering from the company.

William White on InvestorPlace | February 14, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to start another day of trading with a breakdown of the biggest pre-market stock movers investors need to watch for Tuesday!

William White on InvestorPlace | February 14, 2023

Blink Charging (BLNK) Stock Slumps on Public Offering News

Blink Charging (BLNK) stock is sliding lower on Tuesday after revealing pricing and other details from its public offering.

William White on InvestorPlace | February 7, 2023

Read More 'RUBY' Stories Here

RUBY Price Returns

1-mo N/A
3-mo N/A
6-mo 250.88%
1-year 172.73%
3-year -99.76%
5-year -99.65%
YTD 5.26%
2023 -67.43%
2022 -98.19%
2021 27.54%
2020 -20.11%
2019 -40.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!